The multitargeted tyrosine kinase inhibitor (MKI), lenvatinib, is widely used to treat advanced and metastatic thyroid cancer. However, the molecular mechanisms by which thyroid cancer cells become ...
Savolitinib and osimertinib combination significantly improves PFS in EGFR-mutated NSCLC with MET amplification compared to ...
The Organoid group at the Hubrecht Institute have identified a new link between FBXW7 mutations and EGFR signaling activity. The FBXW7 gene is commonly mutated in colorectal cancer and such mutations ...
The multitargeted tyrosine kinase inhibitor (MKI), lenvatinib, is widely used to treat advanced and metastatic thyroid cancer. However, the molecular mechanisms by which thyroid cancer cells become ...
Edward Arrowsmith, MD, MPH, medical director for clinical pathways for OneOncology, discussed treatment challenges in EGFR Exon 20 insertion+ non-small cell lung cancer (NSCLC) and best practices in ...
The RAMOSE and RELAY trials revealed the capacity and constraints of combination therapy with ramucirumab (Cyramza) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC). The phase II RAMOSE ...
Clinical relevance of insulin regulatory pathways in non-small cell lung cancer (NSCLC) progression.
Impact of EGFR and KRAS mutations on survival in 1,000 patients with resected lung adenocarcinoma. Background: Insulin and insulin-like growth factors are key regulators of normal metabolism and ...
Researchers have discovered a cellular partnership that drives the growth of deadly brain tumors and could potentially serve as a novel target for disease treatment. A new study has uncovered a ...
Two microscopy images of human colon organoids. The left image shows an organoid with the FBXW7 mutation (colorectal cancer) and the right image shows an organoid without the mutation (wild type). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback